BACKGROUND: Oxaliplatin use in gastrointestinal malignancies is limited by neurotoxicity. This study aimed to assess the efficacy of pregabalin (LYRICA(R)) in the treatment of oxaliplatin-induced neurotoxicity. PATIENTS AND METHODS: A total of 23 gastrointestinal cancer patients with grade 2 and 3 oxaliplatin-induced sensory neuropathy were treated with pregabalin up to a target dose of 150mg orally (PO) three times a day (tid) based on benefit and tolerance. Neurological symptoms were serially evaluated. RESULTS: The target dose of 150 mg tid provided the best benefit, but patients benefited even at lower doses. Onset of benefit was observed in 2-6 weeks. In the majority of patients (48%), neuropathy improved by 1 to 2 grades. CONCLUSION: Pregabalin significantly reduced the severity of oxaliplatin-induced sensory neuropathy. Being more potent than gabapentin, pregabalin achieved efficacy at lower doses and should lead to fewer dose-related side effects, although this remains to be established in a head-to-head trial.
BACKGROUND:Oxaliplatin use in gastrointestinal malignancies is limited by neurotoxicity. This study aimed to assess the efficacy of pregabalin (LYRICA(R)) in the treatment of oxaliplatin-induced neurotoxicity. PATIENTS AND METHODS: A total of 23 gastrointestinal cancerpatients with grade 2 and 3 oxaliplatin-induced sensory neuropathy were treated with pregabalin up to a target dose of 150mg orally (PO) three times a day (tid) based on benefit and tolerance. Neurological symptoms were serially evaluated. RESULTS: The target dose of 150 mg tid provided the best benefit, but patients benefited even at lower doses. Onset of benefit was observed in 2-6 weeks. In the majority of patients (48%), neuropathy improved by 1 to 2 grades. CONCLUSION:Pregabalin significantly reduced the severity of oxaliplatin-induced sensory neuropathy. Being more potent than gabapentin, pregabalin achieved efficacy at lower doses and should lead to fewer dose-related side effects, although this remains to be established in a head-to-head trial.
Authors: Paul A Glare; Pamela S Davies; Esmé Finlay; Amitabh Gulati; Dawn Lemanne; Natalie Moryl; Kevin C Oeffinger; Judith A Paice; Michael D Stubblefield; Karen L Syrjala Journal: J Clin Oncol Date: 2014-05-05 Impact factor: 44.544
Authors: Deirdre R Pachman; Breanna L Weisbrod; Drew K Seisler; Debra L Barton; Kelliann C Fee-Schroeder; Thomas J Smith; Daniel H Lachance; Heshan Liu; Randy A Shelerud; Andrea L Cheville; Charles L Loprinzi Journal: Support Care Cancer Date: 2014-09-24 Impact factor: 3.603
Authors: Jennifer S Gewandter; Supriya G Mohile; Charles E Heckler; Julie L Ryan; Jeffrey J Kirshner; Patrick J Flynn; Judith O Hopkins; Gary R Morrow Journal: Support Care Cancer Date: 2014-02-16 Impact factor: 3.603